Paradigm Biopharmaceuticals Ltd is an Australian pharmaceutical company specializing in drug repurposing and the development of therapeutic products for various human conditions. With a high ESG risk rating score of 33.4, Paradigm is focused on research and development of treatments for bone marrow edema, Alphavirus, Mucopolysaccharidosis, allergic respiratory conditions such as AR and COPD. Invest in Paradigm for innovative pharmaceutical solutions.